PODD Insulet Corporation
USHealthcareAs of 2026-07-08 16:00
Why PODD matters now
Insulet Corporation (PODD) is a US stock in Healthcare. The latest InvestLog snapshot shows $157.46 with -2.53% on the session and $10.91B in market capitalization; recent performance reads 1-month -5.72% and YTD -48.72%.
The latest financial table shown here is Q1 2026, with revenue of $761.7M, net income of $91.1M, and EPS of $1.30. Investors can compare that operating picture with valuation signals such as P/E 57.68 and FCF yield 4.1%.
The latest indexable market news headline is "ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Insulet Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – PODD" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $219.00; recent insider activity includes BORIO LUCIANA filing S-Sale; recent congressional disclosure data includes Ro Khanna Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
57.68
PEG
—
P/B
7.83
P/S
3.48
EV/EBITDA
18.37
DCF Value
$-37.58
FCF Yield
4.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
71.0%
Operating Margin
17.5%
Net Margin
10.4%
ROE
21.4%
ROA
10.1%
ROIC
16.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $761.7M | $91.1M | $1.30 |
| Q4 2025 | $783.8M | $101.6M | $1.44 |
| FY 2025 | $2.71B | $247.1M | $3.48 |
| Q3 2025 | $706.3M | $87.6M | $1.24 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$223.15
Target (Median)
$219.00
Target Range
$198.00 - $280.00
Trading Activity
Insider Trades
Congress Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Devices
Country
US
Exchange
—
Beta
1.13
Insulet Corporation specializes in the creation, production, and distribution of advanced insulin management systems for individuals living with insulin-dependent diabetes. At the core of their offerings is the Omnipod System, an innovative solution featuring a unique, self-adhesive, and disposable Omnipod device. This tubeless unit can be directly applied to the body for a duration of up to three days, and it operates in conjunction with a wireless handheld personal diabetes manager. The company's products reach customers predominantly through independent distributors and pharmaceutical channels, though direct sales also occur. Geographically, Insulet serves markets spanning the United States, Canada, Europe, the Middle East, and Australia. Established in 2000, the corporation's headquarters are located in Acton, Massachusetts.